Table 2.
Overall and Progression-Free Survival results by PDGFR-β IHC biomarker results.
| Patient Population | PDGFRβ IHC Level |
N | Median OS (mos) |
2-year OS rate |
5-year OS rate |
p-value | Median PFS (mos) |
2-year PFS rate |
5-year PFS rate |
p-value |
|---|---|---|---|---|---|---|---|---|---|---|
| All patients | Low | 35 | 33.6 | 59% | 43% | 0.36 | 18.0 | 41% | 41% | 0.29 |
| Intermediate | 27 | 25.9 | 51% | 30% | 9.6 | 35% | 18% | |||
| High | 21 | 10.1 | 41% | 41% | 4.9 | 40% | 40% | |||
| Sarcomatoid | Low | 4 | 61.8 | 59% | 43% | 0.48 | 59.7 | 41% | 41% | 0.73 |
| Intermediate | 20 | 35.3 | 51% | 30% | 8.1 | 35% | 18% | |||
| High | 19 | 9.7 | 41% | 41% | 4.9 | 40% | 40% | |||
| Control NSCLC | Low | 31 | 33.6 | 97% | 88% | 0.39 | 18.2 | 91% | 85% | 0.22 |
| Intermediate | 7 | 13.3 | 100% | 88% | 9.6 | 96% | 78% | |||
| High | 2 | n/a* | 81% | 76% | n/a* | 80% | 50% |
*
no patients have died yet and a median survival results cannot be obtained